9 assets in Endometrial Disorder

Therapeutic assets addressing Endometrial Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Semaglutide Endometrial Disorder	Washington University School of Medicine	P2	CCC (53)
Zanidatamab Endometrial Disorder	UNICANCER	P2	CCC (53)
Levonorgestrel Endometrial Disorder	Washington University School of Medicine	P2	CCC (52)
Pasifolate Exatecan Endometrial Disorder	Elucida Oncology	P1/2	CCC (48)
Fulvestrant Endometrial Disorder	Pfizer	P1	CC (43)
nkt3447 Endometrial Disorder	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3964 Endometrial Disorder	NiKang Therapeutics, Inc.	P1	CC (43)
pf-07224826 Endometrial Disorder	Pfizer	P1	CC (43)
pf-08052666 Endometrial Disorder	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (43)